Tianjin Development's subsidiary Lishengpharma A's annual net profit increased by 125.6% to 416 million RMB, with a dividend of 60 cents RMB
Tianjin Development (00882.HK) indirectly non-wholly-owned subsidiary Lishengpharma (002393.SZ) announced its full-year results for the year ended last December, with a revenue of RMB 1.392 billion, an increase of 4.2% year-on-year. The net profit was RMB 416 million, an increase of 125.6% year-on-year; earnings per share were RMB 1.62. A cash dividend of RMB 6.00 will be distributed for every 10 shares
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments